AbbVie, Lilly Atopic Dermatitis Treatments Hit With Further Delays With FDA
- AbbVie Inc (NYSE: ABBV) and Eli Lilly And Co (NYSE: LLY) will have to keep waiting for a chance for their JAK inhibitors in atopic dermatitis to see the market.
- The companies separately said on Friday that the FDA again delayed decisions over their applications for Rinvoq (upadacitinib) and Olumiant (baricitinib) in moderate to severe atopic dermatitis.
- Neither provided an updated timeline for the agency's decision.
- Federal regulators are working through safety concerns shrouding Pfizer's JAK inhibitor Xeljanz after a post-marketing study earlier this year turned up risks for dangerous heart side effects and cancer.
- Olumiant, Xeljanz, and Rinvoq already bear boxed warnings about serious infections, blood clots, and cancers.
- As Xeljanz was the first of the class to enter the market, the FDA required Pfizer to conduct a long-term post-marketing study on its product to evaluate those risks further.
- Friday's FDA delay marks the second holdup for Eli Lilly- Incyte Corporation (NASDAQ: INCY) and AbbVie's eczema medicines following an initial setback in April.
- Price Action: LLY stock +0.27% at $232.09, INCY stock -0.94% at $79.25, and ABBV shares +0.44% at $117.69 during the market session on the last check Friday.
- Related content: Benzinga's Full FDA Calendar.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: atopic dermatitis BriefsBiotech News Health Care FDA General Best of Benzinga
